Puneet S. Arora - 03 Sep 2024 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
Chief Medical Officer
Signature
/s/ Kaitlyn Arsenault, as Attorney-in-Fact
Issuer symbol
SKYE
Transactions as of
03 Sep 2024
Net transactions value
$0
Form type
4
Filing time
04 Sep 2024, 18:12:34 UTC
Next filing
26 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SKYE Stock Option (Right to Buy) Award $0 +225,000 $0.000000 225,000 03 Sep 2024 Common Stock 225,000 $5.89 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests 25% on the one year anniversary of the grant date and 1/48th monthly thereafter.